• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

克唑替尼相关肾囊肿的发生可能与ALK阳性非小细胞肺癌患者无进展生存期延长有关：病例报告及文献综述

Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with -positive non-small-cell lung cancer: Case report and review of the literature.

作者信息

Wiest Nathaniel E, Tzou Katherine S, Olson Matthew T, Herchko Steven M, Bajalia Essa M, Thiel David D, Lou Yanyan, Zhao Yujie, Manochakian Rami

机构信息

Department of Internal Medicine Mayo Clinic Florida Jacksonville FL USA.

Department of Radiation Oncology Mayo Clinic Florida Jacksonville FL USA.

出版信息

Clin Case Rep. 2021 Jun 10;9(6):e04278. doi: 10.1002/ccr3.4278. eCollection 2021 Jun.

DOI:10.1002/ccr3.4278
PMID:34136235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8190584/
Abstract

Non-small cell lung cancer patients with anaplastic lymphoma kinase or c-ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib-associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression-free survival.

摘要

接受酪氨酸激酶抑制剂克唑替尼治疗的间变性淋巴瘤激酶或c-ros癌基因1突变的非小细胞肺癌患者很少发生克唑替尼相关肾囊肿（CARCs）。在此，我们报告一例病例并回顾文献，以支持CARCs可能与无进展生存期呈正相关的假说。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/603c5dee3b42/CCR3-9-e04278-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/e64e675a533c/CCR3-9-e04278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/1f213710d124/CCR3-9-e04278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/04adc7f30c19/CCR3-9-e04278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/6962eb8f9fee/CCR3-9-e04278-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/603c5dee3b42/CCR3-9-e04278-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/e64e675a533c/CCR3-9-e04278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/1f213710d124/CCR3-9-e04278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/04adc7f30c19/CCR3-9-e04278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/6962eb8f9fee/CCR3-9-e04278-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba3/8190584/603c5dee3b42/CCR3-9-e04278-g005.jpg

相似文献

1
Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with -positive non-small-cell lung cancer: Case report and review of the literature.克唑替尼相关肾囊肿的发生可能与ALK阳性非小细胞肺癌患者无进展生存期延长有关：病例报告及文献综述
Clin Case Rep. 2021 Jun 10;9(6):e04278. doi: 10.1002/ccr3.4278. eCollection 2021 Jun.
2
Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.克唑替尼相关肾囊肿[CARCs]：发生率及演变模式
Cancer Imaging. 2017 Feb 16;17(1):7. doi: 10.1186/s40644-017-0109-5.
3
Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.中国ALK/ROS1融合阳性非小细胞肺癌患者中Bim缺失多态性的临床特征及其与克唑替尼原发性耐药的关系
Cancer. 2017 Aug 1;123(15):2927-2935. doi: 10.1002/cncr.30677. Epub 2017 Mar 27.
4
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.一名对克唑替尼产生获得性耐药的ALK（间变性淋巴瘤激酶）阳性肺腺癌患者同时发生EGFR（表皮生长因子受体）和KRAS（V-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物）突变：病例报告
BMC Res Notes. 2013 Nov 26;6:489. doi: 10.1186/1756-0500-6-489.
5
Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.克唑替尼进展后不同序贯模式治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌的疗效。
Thorac Cancer. 2022 Jun;13(12):1788-1794. doi: 10.1111/1759-7714.14455. Epub 2022 May 13.
6
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).布加替尼对比阿来替尼用于克唑替尼耐药的晚期间变性淋巴瘤激酶阳性非小细胞肺癌（ALTA-3）。
Future Oncol. 2021 Nov;17(32):4237-4247. doi: 10.2217/fon-2021-0608. Epub 2021 Aug 23.
7
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
8
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.一线劳拉替尼对比克唑替尼治疗晚期ALK阳性非小细胞肺癌患者的疗效和安全性：3期随机开放标签CROWN研究数据的更新分析
Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16.
9
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.阿来替尼对比克唑替尼用于未经治疗的间变性淋巴瘤激酶阳性的非小细胞肺癌亚洲患者（ALESIA）：一项随机的 3 期研究。
Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.
10
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.P-糖蛋白介导间变性淋巴瘤激酶重排非小细胞肺癌对色瑞替尼的耐药性。
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.

引用本文的文献

1
Late-Onset Crizotinib-Associated Renal Cysts With Subsequent Regression Following Dose Reduction: A Case Report.克唑替尼相关迟发性肾囊肿经剂量减少后囊肿消退：一例报告
Thorac Cancer. 2025 Jun;16(12):e70111. doi: 10.1111/1759-7714.70111.
2
Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.一例ALK融合的非小细胞肺癌患者发生克唑替尼相关肾囊肿：病例报告及文献复习
Diagn Pathol. 2024 Apr 14;19(1):58. doi: 10.1186/s13000-024-01480-7.

本文引用的文献

1
Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.克唑替尼在一家中国癌症中心104例ALK重排非小细胞肺癌患者中的真实世界经验
Front Oncol. 2019 Oct 22;9:1116. doi: 10.3389/fonc.2019.01116. eCollection 2019.
2
Crizotinib inhibition of positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.克唑替尼抑制晚期非小细胞肺癌中的阳性肿瘤：加拿大视角。
Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.
3
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
4
Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?克唑替尼治疗期间以及阿来替尼治疗期间复杂肾囊肿的发生：一种可能的药物类别效应？
J Thorac Oncol. 2019 Aug;14(8):e170-e172. doi: 10.1016/j.jtho.2019.03.010.
5
Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation.克唑替尼对原发灶不明的转移性腺癌的完全缓解，该腺癌存在MET扩增和NTRK1共发突变。
Onco Targets Ther. 2019 May 29;12:4261-4267. doi: 10.2147/OTT.S202739. eCollection 2019.
6
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.酪氨酸激酶抑制剂相关不良反应的管理：改善肝细胞癌患者的预后。
Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 May 15.
7
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis.已获批的ALK抑制剂在恶性肿瘤中的安全性及严重不良事件：一项荟萃分析。
Cancer Manag Res. 2019 May 7;11:4109-4118. doi: 10.2147/CMAR.S190098. eCollection 2019.
8
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.MET 外显子 14 跳跃突变阳性非小细胞肺癌对克唑替尼和卡博替尼治疗有反应的病例系列研究。
Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.
9
Renal Injury during Long-Term Crizotinib Therapy.长期克唑替尼治疗期间的肾损伤。
Int J Mol Sci. 2018 Sep 25;19(10):2902. doi: 10.3390/ijms19102902.
10
Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.酪氨酸激酶抑制剂的严重不良反应降低了新诊断的慢性期慢性髓性白血病患者的生存率。
Eur J Haematol. 2018 Jul;101(1):95-105. doi: 10.1111/ejh.13081. Epub 2018 May 23.